This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Background: Interferon β-1a (IFNβ-1a; Avonex) is effective for the treatment of relapsing MS; however, the optimal dose of IFNβ-1a is not known.
Objective: To determine whether IFNβ-1a 60 μg IM once weekly is more effective than IFNβ-1a 30 μg IM once weekly in reducing disability progression in relapsing MS.
Methods: In a double-blind, parallel-group, dose-comparison study, 802 patients with relapsing MS from 38 centers in Europe were randomized to IFNβ-1a 30 μg (n = 402) or 60 μg (n = 400) IM once weekly for ≥36 months. The primary endpoint was disability progression, defined as time to a sustained increase of ≥1.0 point on the Expanded Disability Status Scale (EDSS) persisting for 6 months. Additional endpoints included relapses, MRI, safety, immunogenicity, and subgroup analyses of disability progression.
Results: Both groups showed equal rates of disability progression (hazard ratio, 0.96; 95% CI, 0.77 to 1.20; p = 0.73). In both groups the proportion of subjects with progression of disability by 36 months estimated from Kaplan–Meier curves was 37%. No dose effects were observed on any of the secondary clinical endpoints. Only one MRI measure at one time point, number of new or enlarging T2 lesions at month 36 compared with month 24, showed a difference favoring the 60-μg dose. Both doses were well tolerated; however, slightly higher incidences of flulike symptoms and muscle weakness were observed in the 60-μg group. The incidences of neutralizing antibodies (titers ≥ 20) were 2.3% in the 30-μg group and 5.8% in the 60-μg group.
Conclusion: There was no difference between IFNβ-1a 30 μg and 60 μg IM in clinical or MRI measures.
- Received December 31, 2001.
- Accepted July 11, 2002.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Topics Discussed
Alert Me
Recommended articles
Neutralizing antibodies and efficacy of interferon β-1a
A reassessment of the plateauing relationship between T2 lesion load and disability in MS
Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis
Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis